Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17401022 | 0.92 | RPS6KB1 (0.46) | PDE10ARPS6KB1AKT1TAAR1 | |
| SCHEMBL17401016 | 0.82 | RPS6KB1 (0.44) | RPS6KB1AKT1 | |
| SCHEMBL17401024 | 0.80 | TAAR1 (0.44) | PDE10ARPS6KB1AKT1TAAR1 | |
| SCHEMBL17401023 | 0.80 | TAAR1 (0.44) | PDE10ARPS6KB1AKT1TAAR1 | |
| SCHEMBL17401008 | 0.77 | TAAR1 (0.41) | PDE10ARPS6KB1AKT1TAAR1 | |
| SCHEMBL17396051 | 0.76 | TAAR1 (0.52) | PDE10ATAAR1 | |
| SCHEMBL17396052 | 0.76 | TAAR1 (0.52) | PDE10ATAAR1 | |
| SCHEMBL15720181 | 0.75 | RPS6KB1 (0.54) | RPS6KB1AKT1 | |
| SCHEMBL24956782 | 0.74 | PDE10A (0.52) | PDE10AACP1 | |
| SCHEMBL10099700 | 0.72 | PDE10A (0.58) | PDE10AACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868758-B2 | Betulinic proline imidazole derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2018-01-16 | — | — | US | disclosed |
| US-9868758-B2 | Betulinic proline imidazole derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2018-01-16 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
| WO-2016001820-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, IMPA1 | PDE10A 2228/4885RPS6KB1 2544/4885AKT1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.